Christopher Kramer, MD, Is Study PI on Worldwide Cardiology Research

July 20, 2022 by

UVA is one of 80 sites worldwide studying new therapy for Obstructive Hypertrophic Cardiomyopathy (oHCM). The study is UVA HSR 210472 and is entitled A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction. The study PI is Christopher Kramer, MD, professor and chief of the Cardiovascular Division.

Read Dr. Kramer’s interview with UVA’s Exercise Physiology Core Laboratory.

Original Source

Filed Under: Clinical, Faculty, Research